Ocular adverse effects associated with cyclooxygenase-2 inhibitors.
Casey Eye Institute, Portland, OR 97201, USA. eyedrug@ohsu.edu
Frederick W
FW
Fraunfelder
Jonathan
J
Solomon
Thomas J
TJ
Mehelas
D000328:Adult; D016907:Adverse Drug Reaction Reporting Systems / Q000706:statistics & numerical data; D000368:Aged; D000369:Aged, 80 and over; D000068579:Celecoxib; D003231:Conjunctivitis / Q000139:chemically induced*; D052246:Cyclooxygenase 2 Inhibitors / Q000009:adverse effects*; D017308:Etodolac / Q000009:adverse effects; D006801:Humans; D007555:Isoxazoles / Q000009:adverse effects; D007783:Lactones / Q000009:adverse effects; D008875:Middle Aged; D011720:Pyrazoles / Q000009:adverse effects; D013449:Sulfonamides / Q000009:adverse effects; D013450:Sulfones / Q000009:adverse effects; D014786:Vision Disorders / Q000139:chemically induced*; D000096926:Benzenesulfonamides
D000068579:Celecoxib; D052246:Cyclooxygenase 2 Inhibitors; D017308:Etodolac; D007555:Isoxazoles; D007783:Lactones; D011720:Pyrazoles; D013449:Sulfonamides; D013450:Sulfones; C116926:rofecoxib; C406224:valdecoxib; D000096926:Benzenesulfonamides; C012655:nimesulide